Literature DB >> 34955227

COVID-19: A putative trigger for neuralgic amyotrophy.

G Balloy1, A Magot2, G Fayet2, B Bonnemain2, Y Péréon2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34955227      PMCID: PMC8699330          DOI: 10.1016/j.neurol.2021.11.004

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


× No keyword cloud information.
A 63-year-old man with medical history of diabetes mellitus presented with acute left shoulder pain that began three weeks after a first COVID-19 vaccination (AZD1222) in the left deltoid. The pain was severe, restricted to the left deltoid region and lasted for about three to four days. One week later, he developed left shoulder abduction weakness (Medical Research Council scale 1/5) and left arm external rotation defect, respectively related to supraspinatus and infraspinatus motor deficit, with no passive movement limitation. Neuralgic amyotrophy (NA) was retrospectively evoked when overt amyotrophy of the infraspinatus fossa and dynamic discrete scapular winging appeared. Magnetic resonance imaging (MRI) performed six weeks after pain onset found Short TI Inversion Recovery (STIR) hypersignal in the homolateral supraspinatus and infraspinatus muscles that evoked muscle edema. The first electrodiagnostic (EDX) examination performed six weeks after onset revealed acute denervation in both left upper trapezius and anterior serratus muscles affirming spinal and long thoracic nerve injury in addition to supra-scapular nerve lesion. Needle examination performed two months after onset, as part of EDX testing, revealed an acute denervation pattern in the left infraspinatus and supraspinatus muscles, respectively total and with early reinnervation signs, consistent with NA diagnosis. Given the late diagnosis, no steroids were administrated. Physiotherapy was recommended. The patient received the second injection of the COVID-19 vaccination (AZD1222) with no additional side effect. In the absence of any other potential cause, our patient's NA was considered as possibly related to COVID-19 vaccination. SARS-Cov2 is responsible for neurological manifestations from imprecise mechanisms. It is unclear whether it is related to molecular mimicry, small vessel vasculitis secondary to the cytokine release, hypercoagulable state, auto-immunity, direct effect of the virus, or several of these mechanisms combined [1]. Siepmann et al. discuss possible singularity of COVID-19-associated NA, more likely to cause pure sensory involvement, which remains to be confirmed [2]. The incidence of post-vaccination NA is considered to be very rare. A few cases of NA occurring after COVID-19 vaccination have been reported so far [3]. Previously, NA cases following seasonal influenza vaccination have been reported (vaccine adverse effect reporting system database – VAERS). Exact relationships between NA and vaccination remain unproven but it could be in favor of some immunological mechanism as a trigger of NA. As demonstrated in our case and in the literature, paraclinical confirmation of NA (especially when a differential diagnosis is suspected) can be provided by different modalities, such as EDX or MRI [4], [5]. In conclusion, physicians working in the field of COVID-19 should be aware of possible post-vaccination NA.

Study funding

No targeted funding reported.

Disclosure of interest

The authors declare that they have no competing interest.
  5 in total

1.  Diagnosing neuralgic amyotrophy: Choosing the right test at the right time.

Authors:  Nens Van Alfen
Journal:  Muscle Nerve       Date:  2017-08-29       Impact factor: 3.217

Review 2.  ACR Appropriateness Criteria® Plexopathy.

Authors:  Julie Bykowski; Joseph M Aulino; Kevin L Berger; R Carter Cassidy; Asim F Choudhri; A Tuba Kendi; Claudia F E Kirsch; Michael D Luttrull; Aseem Sharma; Vilaas S Shetty; Khoi Than; Christopher J Winfree; Rebecca S Cornelius
Journal:  J Am Coll Radiol       Date:  2017-05       Impact factor: 5.532

3.  Parsonage Turner syndrome after COVID-19 vaccination.

Authors:  Shalini Mahajan; Felicia Zhang; Arjun Mahajan; Simon Zimnowodzki
Journal:  Muscle Nerve       Date:  2021-05-04       Impact factor: 3.217

Review 4.  Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease.

Authors:  Erin F Balcom; Avindra Nath; Christopher Power
Journal:  Brain       Date:  2021-12-31       Impact factor: 13.501

5.  Variability of symptoms in neuralgic amyotrophy following infection with SARS-CoV-2.

Authors:  Timo Siepmann; Hagen H Kitzler; Heinz Reichmann; Kristian Barlinn
Journal:  Muscle Nerve       Date:  2020-10-14       Impact factor: 3.852

  5 in total
  1 in total

1.  Warm Autoimmune Hemolytic Anemia and Pure Red Cell Aplasia during a Severe COVID-19 B.1.1.7 Infection.

Authors:  Anukul Ghimire; Jaye Platnich; Utkarsh Chauhan
Journal:  Infect Dis Rep       Date:  2022-06-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.